Elizabeth Garcia, PhD

Elizabeth serves as Vice President, Lab Operations and has over 20 years’ experience developing diagnostic assays utilizing a variety of molecular techniques in startup, academic and industry settings.  Elizabeth’s early focus on neurobiology at the HHMI Yale University and Sention led to novel molecular screening methods, ultimately co-founding Primera Diagnostics, a diagnostic company based on proprietary technologies.  Prior to joining Variantyx as Director of Assay Development, Elizabeth was Associate Director at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital.  There she launched clinical high throughput genomic assays aimed at molecularly profiling all tumors presented at DFCI, BWH and Boston Children’s Hospital, developing a cancer database of >30,000 patients with linked clinical information for discovery and personalized cancer medicine.  Elizabeth holds a PhD in Molecular and Cellular Biology from the University of Maryland.